Iconic Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: Atlanta GA United States (2002)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2010
NCT01485588
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Iconic Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (4)

aflibercept (zaltrap) (1 trial)

hi-con1 (2 trials)

icon-1 (2 trials)

ranibizumab (lucentis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Choroidal Neovascularization (Phase 2)

Choroid Neoplasms (Phase 1)

Macular Degeneration (Phase 2)

Melanoma (Phase 1)

Neovascularization, Pathologic (Phase 2)

Uveal Neoplasms (Phase 1)

Wet Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4